What is HC Wainwright’s Estimate for ESPR Q4 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at HC Wainwright issued their Q4 2026 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research report issued to clients and investors on Tuesday, March 10th. HC Wainwright analyst J. Pantginis forecasts that the biopharmaceutical company will post earnings of $0.05 per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.06. The company had revenue of $168.45 million for the quarter, compared to analyst estimates of $165.12 million.

ESPR has been the subject of a number of other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. Piper Sandler initiated coverage on shares of Esperion Therapeutics in a research report on Tuesday, November 25th. They set an “overweight” rating and a $9.00 price objective for the company. Wall Street Zen cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Needham & Company LLC raised their target price on Esperion Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Esperion Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $8.25.

Esperion Therapeutics Stock Down 11.2%

Shares of Esperion Therapeutics stock opened at $2.70 on Wednesday. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $4.18. The company has a market capitalization of $645.46 million, a price-to-earnings ratio of -5.40, a PEG ratio of 0.62 and a beta of 1.11. The firm’s 50-day moving average price is $3.35 and its two-hundred day moving average price is $3.14.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. AIGH Capital Management LLC acquired a new stake in shares of Esperion Therapeutics during the 3rd quarter valued at $7,950,000. Two Seas Capital LP increased its holdings in Esperion Therapeutics by 43.6% in the 2nd quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock worth $9,800,000 after purchasing an additional 3,024,104 shares in the last quarter. Royce & Associates LP acquired a new position in Esperion Therapeutics in the 3rd quarter worth about $6,078,000. Diametric Capital LP raised its position in Esperion Therapeutics by 57.8% in the second quarter. Diametric Capital LP now owns 678,824 shares of the biopharmaceutical company’s stock valued at $668,000 after purchasing an additional 248,648 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Esperion Therapeutics during the third quarter valued at about $476,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Esperion Therapeutics news, CFO Benjamin Halladay sold 7,337 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total value of $26,926.79. Following the sale, the chief financial officer owned 467,525 shares in the company, valued at $1,715,816.75. This trade represents a 1.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 15,543 shares of company stock valued at $55,709 in the last quarter. Company insiders own 1.70% of the company’s stock.

Key Esperion Therapeutics News

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Q4 results beat key Street estimates — EPS $0.22 and revenue $168.45M topped many consensus figures, supporting near-term revenue growth narrative. GlobeNewswire: Esperion Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Company announced an acquisition alongside the quarter; media coverage noted revenue topped forecasts and the deal helped push shares higher in early trading. MSN: Esperion shares rise after revenue tops forecasts and acquisition announced
• Positive Sentiment: HC Wainwright reiterated a Buy and published a Q4 FY2026 EPS projection (J. Pantginis estimating $0.05), which supports bullish analyst sentiment for the stock.
• Neutral Sentiment: Company provided a slide deck and hosted an earnings call — transcripts and presentation materials are available for investors to assess product cadence and forward guidance. Seeking Alpha: Q4 2025 Earnings Call Transcript
• Negative Sentiment: Some outlets described the quarter as “mixed” and one report (Zacks) noted EPS of $0.22 missed its $0.23 estimate — that framing prompted selling pressure and intraday pullbacks. Zacks: Esperion Misses Q4 Earnings Estimates MSN: ESPR stock falls after mixed Q4
• Neutral Sentiment: Reported short-interest data in the recent filings appears anomalous (shows 0 shares/NaN), so short-interest signals are unreliable for trading interpretation until clarified by exchanges/brokers.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.